Sodium-glucose co-transporter type 2 inhibitors and non-alcoholic fatty liver disease
https://doi.org/10.62751/2713-0177-2024-5-3-06
Abstract
Non–alcoholic fatty liver disease (NAFLD) is a general term that includes benign steatosis and non-alcoholic stethohepatitis (NASH) with the possibility of developing liver fibrosis (LF), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), which are natural evolutionary stages of the disease. The widespread prevalence of NAFLD is an extremely urgent medical and social problem for public health systems in most countries of the world. The study of the prevention of NAFLD or slowing the progression of the disease is becoming a global task for the scientific community and practical healthcare. Lifestyle changes remain the main recommendation of treatment, despite various attempts to conduct clinical trials of drugs of a wide pharmacological spectrum. Among the latter, sodium-glucose co-transporter type 2 inhibitors (iNGLT-2) are becoming a promising direction. Processes regulated by the sodium-glucose co-transporter (NGL-2), such as stress on the endoplasmic reticulum (ER) and oxidative stress, sluggish inflammation, autophagy and apoptosis, play an important role in the pathogenesis of NAFLD. In this review, we summarize the current understanding of the pathophysiology of NAFLD and focus on the potential impact of iNGLT-2 on the development and progression of NAFLD, providing current research data in experimental models and clinical practice. Given these findings, further research will contribute to our fuller understanding of the exact mechanisms underlying the pathogenesis of NAFLD and the potential effects of iNGLT-2 in the treatment of NAFLD.
About the Authors
K. M. Shubina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Kseniya M. Shubina – Postgraduate student
Moscow
A. M. Alieva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Amina M. Alieva – C. Sci. (Med.)
Moscow
I. G. Nikitin
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Igor G. Nikitin – Dr. of Sci. (Med), Professor
Moscow
References
1. Andrustakos T, Nasiri-Ansari N, Bakasis AD et al. SGLT-2 inhibitors in NAFLD: Expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022; 23(6): 3107. doi: 10.3390/ijms23063107.
2. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84. doi: 10.1002/hep.28431.
3. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38(2): 420–27. doi: 10.1053/jhep.2003.50320.
4. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123(1): 134–40. doi: 10.1053/gast.2002.34168.
5. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2(11): 901–10. doi: 10.1016/S2213-8587(14)70032-4.
6. Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021; 372: m4747. doi: 10.1136/bmj.m4747.
7. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. doi: 10.1016/j.jhep.2015.11.004.
8. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328–57. doi: 10.1002/hep.29367.
9. Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7): 1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312.
10. Fouad Y, Waked I, Bollipo S et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’ Liver Int. 2020; 40(6): 1254–61. doi: 10.1111/liv.14478.
11. Rinaldi L, Pafundi PC, Galiero R et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021; 10(2): 270. doi: 10.3390/antiox10020270.
12. Masarone M, Rosato V, Aglitti A et al. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS ONE. 2017; 12(6): e0178473. doi: 10.1371/journal.pone.0178473.
13. Tanase DM, Gosav EM, Costea CF et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196. doi: 10.1155/2020/3920196.
14. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37): 13306–24. doi: 10.3748/wjg.v20.i37.13306.
15. Galiero R, Caturano A, Vetrano E et al. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021; 22(3): 755–68. doi: 10.31083/j.rcm2203082.
16. Petta S, Argano C, Colomba D et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. J Hepatol. 2015; 62(4): 928–33. doi: 10.1016/j.jhep.2014.11.030.
17. U.S. Food and Drug Administration (FDA) FDA Approves New Treatment for a Type of Heart Failure. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
18. U.S. Food and Drug Administration (FDA) FDA Approves Treatment for Chronic Kidney Disease. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease
19. Kim JW, Lee YJ, You YH et al. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and alpha-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem. 2018; 120(5): 8534–46. doi: 10.1002/jcb.28141.
20. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016; 65(8): 1038–48. doi: 10.1016/j.metabol.2015.12.012.
21. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018; 68(2): 268–79. doi: 10.1016/j.jhep.2017.09.003.
Review
For citations:
Shubina K.M., Alieva A.M., Nikitin I.G. Sodium-glucose co-transporter type 2 inhibitors and non-alcoholic fatty liver disease. FOCUS. Endocrinology. 2024;5(3):45-54. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-3-06
Views:
78
Email this article 